Identification of the human cytochromes P450 involved in the oxidative metabolism of 'Ecstasy'-related designer drugs

Biochemical Pharmacology

Volumn 59, Issue 12, 2000, Pages 1563-1571

  Kreth, Klaus Peter ^a   Kovar, Karl Artur ^a   Schwab, Matthias ^b   Zanger, Ulrich M ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

CYP2D6; Cytochrome P450; Designer drugs; Ecstasy; MDE; MDMA

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; PHENACETIN O DEETHYLASE; RECOMBINANT ENZYME;

AEROBIC METABOLISM; ARTICLE; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; ENZYME ACTIVITY; FLUORESCENCE; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; DESIGNER DRUGS; HUMANS; KINETICS; MICROSOMES, LIVER; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXIDATION-REDUCTION; OXIDOREDUCTASES;

EID: 0034092057     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00284-7     Document Type: Article

References (37)

1. Nichols D.E. Differences between the mechanism of action of MDMA, MBDB and the classic hallucinogens. Identification of a new therapeutic class entactogens . J Psychoactive Drugs. 18:1986;305-313.
2. Steele T.D., McCann U.D., Ricaurte G.A. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") Pharmacology and toxicology in animals and humans . Addiction. 89:1994;539-551.
3. Ricaurte G., Bryan G., Strauss L., Seiden L., Schuster D. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science. 229:1985;986-988.
4. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther. 240:1987;1-7.
5. Scheffel U., Szabo Z., Mathews W.B., Finley P.A., Dannals R.F., Ravert H.T., Szabo K., Yuan J., Ricaurte G.A. In vivo detection of short- and long-term MDMA neurotoxicity-a positron emission tomography study in the living baboon brain. Synapse. 29:1998;183-192.
6. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet. 352:1998;1433-1437.
7. Bolla K.I., McCann U.D., Ricaurte G.A. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology. 51:1998;1532-1537.
8. Morgan M.J. Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology. 19:1998;252-264.
9. Henry J.A., Jeffreys K.J., Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine. Lancet. 340:1992;384-387.
10. Milroy C.M., Clark J.C., Forrest A.R. Pathology of deaths associated with "ecstasy" and "eve" misuse. J Clin Pathol. 49:1996;149-153.
11. McCann U.D., Ricaurte G.A. Lasting neuropsychiatric sequelae of (+)-methylenedioxymethamphetamine ('ecstasy') in recreational users. J Clin Psychopharmacol. 11:1991;302-305.
12. McCann U.D., Slate S.O., Ricaurte G.A. Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy'). Drug Saf. 15:1996;107-115.
13. Lim H.K., Foltz R.L. In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in rat Identification of metabolites using an ion trap detector . Chem Res Toxicol. 1:1988;370-378.
14. Hiramatsu M., Kumagai Y., Unger S.E., Cho A.K. Metabolism of methylenedioxymethamphetamine Formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct . J Pharmacol Exp Ther. 254:1990;521-527.
15. Ensslin H.K., Maurer H.H., Gouzoulis E., Hermle L., Kovar K.A. Metabolism of racemic 3,4-methylenedioxyethylamphetamine in humans. Isolation, identification, quantification, and synthesis of urinary metabolites. Drug Metab Dispos. 24:1996;813-820.
16. Lim H.K., Foltz R.L. Ion trap mass spectrometric evidence for the metabolism of 3,4-(methylenedioxy)-methamphetamine to the potent neurotoxins 2,4,5-trihydroxymethamphetamine and 2,4,5-trihydroxyamphetamine. Chem Res Toxicol. 4:1991;626-632.
17. Kumagai Y., Lin L.Y., Hiratsuka A., Narimatsu S., Suzuki T., Yamada H., Oguri K., Yoshimura H., Cho A.K. Participation of cytochrome P450-2B and -2D isozymes in the demethylenation of methylenedioxymethamphetamine enantiomers by rats. Mol Pharmacol. 45:1994;359-365.
18. Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y., Hiratsuka A., Schmitz D.A., Chu T.Y. The demethylenation of methylenedioxyamphetamine ("Ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol. 47:1994;1151-1156.
19. Lin L.Y., Di Stefano E.W., Schmitz D.A., Hsu L., Ellis S.W., Lennard M.S., Tucker G.T., Cho A.K. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos. 25:1997;1059-1064.
20. Braun U., Shulgin A.T., Braun G. Centrally active N-substituted analogues of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine). J Pharm Sci. 69:1980;192-195.
21. Zanger U.M., Vilbois F., Hardwick J.P., Meyer U.A. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry. 27:1988;5447-5454.
22. Evert B., Eichelbaum M., Haubruck H., Zanger U.M. Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells. Naunyn Schmiedebergs Arch Pharmacol. 355:1997;309-318.
23. Brunnenberg M., Lindenblatt H., Gouzoulis-Mayfrank E., Kovar K.A. Quantitation of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma by high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Sci Appl. 719:1998;79-85.
24. Zanger U.M., Hauri H.P., Loeper J., Homberg J.C., Meyer U.A. Antibodies against human cytochrome P-450db1 in autoimmune hepatits type II. Proc Natl Acad Sci USA. 85:1988;8256-8260.
25. Belloc C., Baird S., Cosme J., Lecoeur S., Gautier J.C., Challine D., de Waziers I., Flinois J.P., Beaune P.H. Human cytochromes P450 expressed in Escherichia coli Production of specific antibodies . Toxicology. 106:1996;207-219.
26. Newton D.J., Wang R.W., Lu A.Y. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos. 23:1995;154-158.
27. Drahushuk A.T., McGarrigle B.P., Larsen K.E., Stegeman J.J., Olson J.R. Detection of CYP1A1 protein in human liver and induction by TCDD in precision-cut liver slices incubated in dynamic organ culture. Carcinogenesis. 19:1998;1361-1368.
28. Lewandowski M., Chui Y.C., Levi P.E., Hodgson E. Differences in induction of hepatic cytochrome P450 isozymes by mice in eight methylenedioxyphenyl compounds. J Biochem Toxicol. 5:1990;47-55.
29. Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals Studies with liver microsomes of 30 Japanese and 30 Caucasians . J Pharmacol Exp Ther. 270:1994;414-423.
30. Johnson M., Letter A.A., Merchant K., Hanson G.R., Gibb J.W. Effects of 3,4-methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine (MDMA) isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. J Pharmacol Exp Ther. 244:1988;977-982.
31. Chu T., Kumagai Y., DiStefano E.W., Cho A.K. Disposition of methylenedioxymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol. 51:1996;789-796.
32. Code E.L., Crespi C.L., Penman B.W., Gonzalez F.J., Chang T.K., Waxman D.J. Human cytochrome P4502B6 Interindividual hepatic expression, substrate specifity, and role in procarcinogen activation . Drug Metab Dispos. 25:1997;985-993.
33. Tucker G.T. Adam and Eve make love. Analysis of the enantiomers of 3,4-methylenedioxy-N-ethylamphetamine (MDE, "Eve") and its metabolite 3,4-methylenedioxyamphetamine (MDA) in rat brain. Hum Exp Toxicol. 15:1996;455-457.
34. Hermle L., Spitzer M., Borchardt D., Kovar K.A., Gouzoulis E. Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacology. 8:1993;171-176.
35. Schwab M., Griese U., Hermle L., Gouzoulis E., Zanger U.M., Mikus G. Is there an impact of CYP2D6 genotype on the toxicity of 'ecstasy' and related designer drugs? Naunyn Schmiedebergs Arch Pharmacol. 357:(Suppl):1998;R163.
36. Schwab M., Seyringer E., Brauer R.B., Hellinger A., Griese E.U. Fatal MDMA intoxication. Lancet. 353:1999;593-594.
37. Henry J.A., Hill I.R. Fatal interaction between ritonavir and MDMA. Lancet. 352:1998;1751-1752.